Theravance Valuation Multiples

Discover Theravance's revenue and EBITDA valuation multiples and investment history, alongside public comparables like PeptiDream, Youcare Pharmaceutical, Aclaris Therapeutics, Keqian Biology and more.

Theravance Overview

About Theravance

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).


Founded

2013

HQ

United States

Employees

97

Financials (LTM)

Revenue: $92M
Net Income: $133M

EV

$538M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Theravance Financials

Theravance reported last 12-month revenue of $92M.

In the same LTM period, Theravance generated $92M in gross profit and $133M in net income.

Revenue (LTM)


Theravance P&L

In the most recent fiscal year, Theravance reported revenue of $107M and EBITDA of $124M.

Theravance is profitable as of last fiscal year, with gross margin of 100%, EBITDA margin of 116%, and net margin of 99%.

See analyst estimates for Theravance
LTMLast FY202320242025202620272028
Revenue$92M$107M$57M$64M$107M
Gross Profit$92M$107M--$107M
Gross Margin100%100%--100%
EBITDA-$124M($43M)($38M)$124M
EBITDA Margin-116%(74%)(60%)116%
EBIT Margin28%(3%)(93%)(66%)(3%)
Net Profit$133M$106M($55M)($56M)$106M
Net Margin144%99%(96%)(88%)99%
Net Debt-($125M)---

Financial data powered by Morningstar, Inc.

Theravance Stock Performance

Theravance has current market cap of $887M, and enterprise value of $538M.

Market Cap Evolution


Theravance's stock price is $17.08.

Theravance share price increased by 0.2% in the last 30 days, and by 17.7% in the last year.

Theravance has an EPS (earnings per share) of $2.04.

See more trading valuation data for Theravance
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$538M$887M0.0%0.2%0.5%17.7%$2.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Theravance Valuation Multiples

Theravance trades at 5.8x EV/Revenue multiple, and 4.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Theravance

EV / Revenue (LTM)


Theravance Financial Valuation Multiples

As of September 4, 2026, Theravance has market cap of $887M and EV of $538M.

Theravance has a P/E ratio of 6.6x.

LTMLast FY202320242025202620272028
EV/Revenue5.8x5.0x9.4x8.4x5.0x
EV/EBITDA-4.3x(12.6x)(14.0x)4.3x
EV/EBIT20.9x(149.3x)(10.1x)(12.7x)(149.3x)
EV/Gross Profit5.8x5.0x--5.0x
P/E6.6x8.4x(16.1x)(15.7x)8.4x
EV/FCF-2.3x(18.2x)(45.3x)2.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Theravance Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Theravance Margins & Growth Rates

Theravance decreased revenue by 21% but net profit grew by 38% in the last fiscal year.

In the most recent fiscal year, Theravance reported gross margin of 100%, EBITDA margin of 116%, and net margin of 99%.

See estimated margins and future growth rates for Theravance

Theravance Margins

Last FY202420252026202720282029
Gross Margin100%-100%100%
EBITDA Margin116%(60%)116%-
EBIT Margin(3%)(66%)(3%)46%
Net Margin99%(88%)99%172%
FCF Margin222%(18%)222%-

Theravance Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(21%)12%67%(21%)
Gross Profit Growth(21%)--(21%)
EBITDA Growth-(10%)(423%)-
EBIT Growth(1201%)(20%)(92%)(1201%)
Net Profit Growth38%2%(288%)38%
FCF Growth-(60%)(2110%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Theravance Operational KPIs

Theravance's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.1M for the same period.

Access forward-looking KPIs for Theravance
LTMLast FY202320242025202620272028
Revenue per Employee-$1.1M---
Opex per Employee-$1.1M---
G&A Expenses to Revenue80%69%--69%
R&D Expenses to Revenue24%35%71%58%35%
Opex to Revenue-103%193%166%103%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Theravance Competitors

Theravance competitors include PeptiDream, Youcare Pharmaceutical, Aclaris Therapeutics, Keqian Biology, Rigel Pharmaceuticals, HK inno.N, DBV Technologies, Biotest, TchaikaPharma and Annexon.

Most Theravance public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
PeptiDream7.2x3.7x(45.5x)16.8x
Youcare Pharmaceutical2.1x-(321.6x)-
Aclaris Therapeutics100.2x119.7x(10.9x)-
Keqian Biology4.2x4.4x7.5x8.2x
Rigel Pharmaceuticals2.9x2.8x6.6x8.6x
HK inno.N1.4x1.4x10.1x8.9x
DBV Technologies-149.9x(5.0x)(4.8x)
Biotest----

This data is available for Pro users. Sign up to see all Theravance competitors and their valuation data.

Start Free Trial

Investments by Theravance

Theravance has invested in 1 company to date.

Latest investment by Theravance was on June 3rd 2021. Theravance invested in ImaginAb in their $13M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Theravance

ImaginAb
Description
ImaginAb is a Gothenburg-based biotechnology company developing minibodies and diabodies for immunoPET imaging and radiopharmaceutical therapies. Its lead 89Zr-DFO-ABY-025 targets HER2 in breast cancer trials, while CD8 ImmunoPET licenses to Merck and Bristol Myers Squibb for immunotherapy monitoring. Phase II studies enroll patients across US and Europe. Founded in 2010, ImaginAb collaborates with 15 pharma partners worldwide.
HQ CountryUnited States
HQ City
Los Angeles, CA
Deal Date3 Jun 2021
RoundSeries A
Raised$13M
InvestorsTheravance; James Pallotta; Cycad Group; Adage Capital Management; Norgine Ventures
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Theravance investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Theravance

When was Theravance founded?Theravance was founded in 2013.
Where is Theravance headquartered?Theravance is headquartered in United States.
How many employees does Theravance have?As of today, Theravance has over 97 employees.
Who is the CEO of Theravance?Theravance's CEO is Rick E. Winningham.
Is Theravance publicly listed?Yes, Theravance is a public company listed on Nasdaq.
What is the stock symbol of Theravance?Theravance trades under TBPH ticker.
When did Theravance go public?Theravance went public in 2014.
Who are competitors of Theravance?Theravance main competitors include PeptiDream, Youcare Pharmaceutical, Aclaris Therapeutics, Keqian Biology, Rigel Pharmaceuticals, HK inno.N, DBV Technologies, Biotest, TchaikaPharma, Annexon.
What is the current market cap of Theravance?Theravance's current market cap is $887M.
What is the current revenue of Theravance?Theravance's last 12 months revenue is $92M.
What is the current revenue growth of Theravance?Theravance revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Theravance?Current revenue multiple of Theravance is 5.8x.
What is the current net income of Theravance?Theravance's last 12 months net income is $133M.
How many companies Theravance has acquired to date?Theravance hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Theravance has invested to date?As of September 2026, Theravance has invested in 1 company.
What was the last Theravance investment?On 3rd June 2021 Theravance invested in ImaginAb, participating in a $13M Series A round, alongside James Pallotta, Cycad Group, Adage Capital Management, and Norgine Ventures.
In what companies Theravance invested in?Theravance invested in ImaginAb.

See public comps similar to Theravance

Lists including Theravance

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial